Navigation Links
China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
Date:2/11/2009

HAIKOU CITY, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced today that the company has initiated clinical trials for the generic version of the leading hypertension drug Candesartan.

The clinical trials for this product are anticipated to require approximately 18 months to complete. The sartan group of drugs, used as front- line therapy in the treatment of hypertension, are usually well-tolerated, and have a high safety record. Candesartan was discovered and originally synthesized by the Japanese firm, Takeda Pharmaceutical Company Limited and jointly developed by the same company with AstraZeneca. Worldwide sales for 2007 exceeded $2.5 billion(1). In China, Candesartan is listed on the National Basic Medical Insurance Drug List, enabling patient reimbursement.

China Pharma's CEO and president, Ms Zhilin Li, commented, ''In China today, nearly 60% of all urban adults aged 65 years and over suffer from hypertension(2). Moreover, due to the aging of the population and changes in lifestyle, the urban prevalence of hypertension has been predicted to grow to 100 million by 2011(2). Even in 2004, sales in China of anti-hypertension drugs exceeded CNY 10 billion ($1.2 billion, Dec. 2004), exhibiting a market growth of over 30% year on year, and accounting for 22% of all cardiovascular system drugs sold in China(3). Hypertension is a serious problem and is linked to an increased incidence of other diseases, particularly brain edema, coronary heart disease and diabetes. Candesartan is a well established hypertension drug and is known to be particularly suitable for heart failure and diabetic patients. Our R&D strategy is to enable us to provide more effective treatment for the high numbers of patients in China whose medication needs are serious
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Syngenta Enters Into Research Collaboration With Anhui Academy, China
3. China Sky One Medical, Inc. CFO to Present at Roth Conference
4. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
5. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
6. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
7. China Biologic Products Enters into Short-Term Loan Agreement
8. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
9. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
10. China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate
11. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... , , , , , , Other important parameters for optimizing electroporation. , , ... Field strength , , ... field pulses , Adjustment , ... of DNA/RNA , Influence , ...
... , , Dr. Frank Stahl , ... (Society for Biotechnological Research) , , , , , ... DNA microarrays are a key technology in modern molecular biotechnology. , ... of complex genetic changes, thereby enabling a deeper insight ...
... , , Note: Genomic DNA is fragile. High molecular weight DNA ... tips or equipment when , pipetting genomic DNA. Do not vortex ... Place a 1 cm tail sample into a 1.5 ml microcentrifuge tube; ... To minimize possible cross-contamination, , do not ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Optimizing electroporation parameters 6An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 2An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 3An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 4An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 5An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 6Mouse Tail Genomic DNA Isolation Protocol(1) 2
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... , WHAT: EPA,s top scientist and the ,father of ... our nation,s first preeminent scientist and inventor Benjamin Franklin ... Philadelphia Science Festival. Park visitors and local college ... innovation and invention, and how the current generation can ...
... high-quality assisted reproduction treatment as defined by the European ... ESHRE position paper on Good clinical treatment in Assisted ... patients should be treated the same and with the ... not always the case. The Guide is based ...
... professor in the Virginia Tech Carilion Research Institute and ... and Sciences, has been invited to speak at a ... 11-12 on the security implications of advances in neuroscience. ... four-part policy study on neuroscience and society called Brain ...
Cached Biology News:ESHRE sets standards for cross-border reproductive care 2ESHRE sets standards for cross-border reproductive care 3
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives that ... (trxB) and glutathione reductase (gor) genes, which ... cytoplasm. Studies have shown that expression in ... in another host even though overall expression ...
... Ultrospec 6300 pro UV/Visible Spectrophotometer: ... Pharmacopoeia in terms of instrument specification and ... able to be used for rapid, discrete ... scanning capability., *Press to read high performance ...
Biology Products: